

Teresa Morã;n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9614503/publications.pdf>

Version: 2024-02-01

23
papers

5,396
citations

687220

13
h-index

677027

22
g-index

24
all docs

24
docs citations

24
times ranked

6959
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. <i>Clinical Lung Cancer</i> , 2022, 23, 300-310.	1.1	12
2	The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. <i>Autophagy</i> , 2021, 17, 1349-1366.	4.3	72
3	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. <i>Lung Cancer</i> , 2021, 153, 25-34.	0.9	17
4	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	1.3	11
5	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2560-2567.	1.2	7
6	Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma. <i>Lung Cancer</i> , 2020, 140, 42-45.	0.9	15
7	IgA vasculitis and polymyalgia rheumatica induced by durvalumab. <i>Translational Lung Cancer Research</i> , 2020, 9, 421-423.	1.3	4
8	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	0.5	29
9	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	0.5	34
10	The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1163-1179.	2.3	16
11	Clinical Activity of Afatinib in Patients With Non-“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. <i>Clinical Lung Cancer</i> , 2020, 21, 428-436.e2.	1.1	14
12	A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1588-1597.	1.2	12
13	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. <i>Revista Espanola De Patologia</i> , 2020, 53, 140-148.	0.6	0
14	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87.	0.9	29
15	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.	0.9	10
16	Is more the better?â€”cetuximab in non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2018, 7, S195-S197.	1.3	1
17	Monitoring <i>EGFR</i>-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. <i>Oncotarget</i> , 2018, 9, 27074-27086.	0.8	8
18	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 88, 63-69.	0.9	78
20	The epidermal growth factor receptor (EGFR) in lung cancer. <i>Translational Respiratory Medicine</i> , 2015, 3, 1.	3.8	34
21	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. <i>Translational Lung Cancer Research</i> , 2015, 4, 678-88.	1.3	16
22	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 128-41.	1.3	16
23	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943